These positive findings were further corroborated by data from a metanalysis conducted by Nourelden et al. to assess the safety and efficacy of teplizumab for the treatment of T1DM.97 Eight randomized clinical trials involving 866 patients found that subjects treated with teplizumab had lower insulin use and higher area under the curve of C-peptide compared with placebo. This evidence concerns the gene INS and type 1 diabetes mellitus.